John S. Sampalis, B.Sc., B.A. (Hon.), M.Sc., Ph.D., F.A.C.E.
Chief Scientific Officer & Co-Founder
As Chief Scientific Officer and Co-Founder of Axios Investments Corporation, Dr. Sampalis brings over twenty – five years of experience epidemiology, health economics and evaluation of health care including the assessment of the benefits and risks of new therapeutic products and interventions. During his career Dr. Sampalis has worked with governments, academics and the Industry in the assessment of health services. He is founder and CEO of JSS Medical Research Inc. , a leading Montreal-based global clinical research organization that was established in 1997.
He is a tenured professor of Surgery and Epidemiology & Biostatistics of McGill University, the University of Montreal and University of Laval. Throughout his career he has received numerous scholarships from provincial and federal funding agencies including the Medical Research Council of Canada, the National Health Development Program and the Fonds de la recherche en santé du Quebec. With over 130 peer reviewed publications in high ranking journals and more than seven million dollars in research funding, Dr. Sampalis is recognized as one of the leading clinical epidemiologists in the world.
Possessing extensive expertise in health services research, health economics, clinical trials and the evaluation of pharmaceuticals and medical technology, Dr. Sampalis also offers services as a Research and Epidemiological Consultant for numerous pharmaceutical companies, hospitals and government organizations and agencies.
Dr. Sampalis is recognized as one of Canada’s leading epidemiologist, as well as the top trauma researcher in Canada. He participates as a reviewer for over five leading peer reviewed journals and as a committee member for provincial and federal funding agencies.
As Chief Scientific Officer & Founder of Axios Investments Corporation, he oversees all scientific aspects of target opportunities through the evaluation of the scientific accuracy and validity as well as the assessment of the potential market and demand with emphasis on the long term market value based on disease epidemiology, treatment gaps and competitive environment. This ensures an accurate and evidence based assessment of the likelihood of success and risk that will allow valid risk based valuation of opportunities for investment in health care products.
Nicholas P. Katsepontes, BA, LLB, LLM
President, CEO & Co-Founder
Nicholas P. Katsepontes has over 25 years of legal and business experience providing counsel and business advice to shipping, biotechnology, and hi-tech companies.
Nicholas started his legal career in Halifax, Nova Scotia in 1988 where he practiced shipping, marine, and corporate law for an established law firm. He moved to Ottawa in 1992 to serve as a Special Advisor to the Ministry of Foreign Affairs and International Trade (DFAIT) providing strategic and legal advice in relation to Canada’s maritime and fisheries law and policy. He has worked and published papers in the areas of law of the sea, fisheries management, ship registrations, and oil and gas development in closed seas.
He is a Co-Founder and acting CEO and President of Semintha Nutraceuticals Ltd. – the first company in the portfolio of Axios Investments Corporation.
Nicholas has also served in the past as VP Investment Banking and Legal Counsel of an Ottawa based boutique investment bank. As well he previously served as Vice-President Corporate Affairs and Legal Counsel for JSS Medical Research Inc. a Montreal based clinical research organization specializing in nutraceutical and pharmaceutical products and assisting that company in its corporate reorganization as well as acquisition and merger strategies.
He has served as a director of a number of leading edge technology companies including SWIX (corporate metrics) and an early advisor and legal counsel to Jaded Pixel Technologies Inc./Shopify a leading Ottawa based E-commerce Company.
He holds a Bachelors degree in Economics from Dalhousie University, undertook graduate studies in international economics, holds a Bachelor of Law and Master of Law (shipping and trade law) degrees from Dalhousie Law School, and is a member of the Nova Scotia Barrister’s Society as well as the Law Society of Upper Canada.
Sanjay Machado, MD
Vice-President – Business Development
Dr. Machado obtained his MD from University of Pune, India. He specialized in family medicine and held private practice. He has authored several publications and presented abstracts and posters at international conferences. He has over 18 years’ experience in multinational pharmaceutical, CRO, Bioequivalence & Phase I and Site Management Organizations. He held management positions at ICON Clinical Research plc, Venn Life Sciences, ADA Medical Ltd, AstraZeneca & Biovail Contract Research and JSS Medical Research Inc. His previous job descriptions included his responsibilities for global expansion through mergers and acquisitions, providing logistical support to clinical operations and oversight of global studies.
Dr. Machado has worked on products in several therapeutic areas including; Gastroenterology, CVS, Respiratory, Dermatology, Endocrinology, Obstetrics & Gynaecology, Oncology, Radiology, Psychiatry and CNS. He also has clinical experience in generic drug development, medical devices and radio nuclear imaging studies. His background and exposure to the commerce of science allows him to understand emerging trends and the needs of existing pharmaceutical.
Stella Boukas, BA, CCRP
Vice President of Clinical Study Evaluations
Ms. Boukas holds a Bachelor’s degree in Psychology from McGill University with training in Epidemiology and Biostatistics. She has also been certified by the Society of Clinical Research Associates (SOCRA) as a Certified Clinical Research Professional (CCRP). She has over 25 years of experience in medical research management including Clinical Trials (Phase II-III), Observational Studies, Chart Reviews and Literature Reviews.
Ms. Boukas brings substantial expertise to the design and implementation of value-add clinical trials for emerging and early stage companies. She has managed IT and QA as well as data management teams in the context of major clinical studies
Emmanouil Rampakakis, PhD
Senior Scientific Advisor
Dr. Rampakakis received his Ph.D. from the Department of Biochemistry in McGill University and the McGill Cancer Centre, and obtained post-doctoral training in Pharmacoepidemiology at McGill University and the Jewish General Hospital.
Dr. Rampakakis has over 10 years of experience in scientific research and has contributed in the conception, design, analysis and interpretation of several large scale, national and international, registrational and observational studies. He has numerous peer review publications at high impact scientific journals (e.g. Nature, Journal of Bone and Mineral Research, Arthritis Care & Research), and presentations at international conferences. In addition he serves as a reviewer for four peer review journals.
Michael Farley, PhD
Senior Investment Advisor
Dr. Farley is a former Canadian Diplomatic and Trade Commissioner with over twenty-years of experience having worked extensive in the international life sciences sector. He is fluent in four languages. He founded a number of companies working or investing in the biotechnology sector and he has a network of private equity, venture capital and limited partnership fund managers that spans the globe.
Dr. Farley is also a frequent advisor to a number of government on bioregion development and investment including the biotechnology sector.